Halozyme Therapeutics to Hold 2006 Fourth Quarter and Year End Conference Call on March 8
March 06 2007 - 8:00AM
PR Newswire (US)
SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics,
Inc. (AMEX:HTI), a biopharmaceutical company developing and
commercializing recombinant human enzymes, today announced that it
will release financial results for the three and twelve months
ended December 31, 2006 prior to market open on Thursday, March 8,
2007. Jonathan Lim, MD, President and Chief Executive Officer,
Gregory Frost, PhD, Vice President and Chief Scientific Officer,
and David Ramsay, Vice President and Chief Financial Officer, will
host an investment community conference call beginning at 8:00 a.m.
PT (11:00 a.m. ET) on Thursday, March 8, 2007, to discuss these
results and provide a business update. Individuals interested in
participating in the conference call may do so by dialing
888-463-4487 for domestic callers, or 706-679-5355 for
international callers. Those interested in listening to the
conference call live via the Internet may do so by visiting the
Investor Relations section of the Company's website at
http://www.halozyme.com/. A replay will be available on Halozyme's
website for 30 days. A telephone replay will be available for 48
hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for
international callers, and entering reservation number 1353453.
About Halozyme Therapeutics, Inc. Halozyme is a biopharmaceutical
company developing and commercializing recombinant human enzymes
for the drug delivery, palliative care, oncology, and infertility
markets. The company's portfolio of products is based on
intellectual property covering the family of human enzymes known as
hyaluronidases. The company's Enhanze(TM) Technology is a novel
drug delivery platform designed to increase the absorption and
dispersion of biologics. Its first partnership is with Roche to
apply Enhanze Technology to Roche's biological therapeutic
compounds for 13 targets. In addition, the company has received FDA
approval for two products: Cumulase(R) and Hylenex, for use as an
adjuvant to increase the absorption and dispersion of other
injected drugs and fluids. The Company also has a number of
different enzymes in its portfolio that are targeting significant
areas of unmet need. Halozyme Contact Investor Relations Contact
David A. Ramsay Don Markley Chief Financial Officer
Lippert/Heilshorn & Associates (858) 794-8881 (310) 691-7100
DATASOURCE: Halozyme Therapeutics, Inc. CONTACT: David A. Ramsay,
Chief Financial Officer of Halozyme Therapeutics, Inc.,
+1-858-794-8881, ; or Investor Relations, Don Markley of
Lippert/Heilshorn & Associates, +1-310-691-7100, , for Halozyme
Therapeutics, Inc. Web site: http://www.halozyme.com/
Copyright
Halozyme Therapeutic (AMEX:HTI)
Historical Stock Chart
From Apr 2024 to May 2024
Halozyme Therapeutic (AMEX:HTI)
Historical Stock Chart
From May 2023 to May 2024